Efficacy observation of P-Gemox chemotherapy combined with intensity modulated radiotherapy in treatment of extranodal NK/T cell lymphoma, nasal type
10.3760/cma.j.cn115356-20200507-00117
- VernacularTitle:P-Gemox方案化疗联合调强适形放疗治疗结外鼻型NK/T细胞淋巴瘤效果观察
- Author:
Yan DU
1
;
Yunhong HUANG
;
Yunfei HU
;
Mengxiang CHEN
;
Shuhui ZHOU
;
Chunxia SHI
Author Information
1. 贵州医科大学附属肿瘤医院 贵州省肿瘤医院淋巴瘤科，贵阳 550004
- From:
Journal of Leukemia & Lymphoma
2020;29(11):666-670
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the therapeutic efficacy and side effects of P-Gemox regimen combined with intensity modulated radiotherapy in the treatment of extranodal NK/T cell lymphoma, nasal type (ENKTL).Methods:The data of 60 patients with ENKTL confirmed by pathomorphology and immunohistochemistry in Guizhou Cancer Hospital from July 2014 to October 2019 were retrospectively analyzed. All patients received P-Gemox chemotherapy combined with intensity modulated radiotherapy (at least 2 cycles), and the efficacy and adverse reactions were evaluated.Results:The complete remission rate of 60 patients was 65.0% (39/60), the partial remission rate was 25.0% (15/60), and the total effective rate was 90.0% (54/60). The main side reactions were myelosuppression, transaminase elevation and radiation mucositis; most of them were mild to moderate, which were relieved after treatment or the withdrawal of radiotherapy and chemotherapy. No treatment-related death cases were found. The overall survival rate of 1-year, 2-year, 3-year was 91%, 75% and 69%; the progression-free survival rate of 1-year, 2-year, 3-year was 86%, 68% and 62%. During the treatment, 3 cases died due to the progress of the disease and infection. Multivariate analysis showed that with and without hemophagocytic syndrome and radiotherapy dose were related to prognosis (all P < 0.05). Conclusion:P-Gemox, as the first-line induction chemotherapy regimen combined with intensity modulated radiotherapy has good short-term efficacy and safety for patients with ENKTL.
